Natera, Inc. (NTRA)
NASDAQ: NTRA · Real-Time Price · USD
231.25
-9.09 (-3.78%)
At close: Jan 16, 2026, 4:00 PM EST
231.52
+0.27 (0.12%)
After-hours: Jan 16, 2026, 7:03 PM EST
Natera Employees
Natera had 4,434 employees as of December 31, 2024. The number of employees increased by 1,141 or 34.65% compared to the previous year.
Employees
4,434
Change (1Y)
1,141
Growth (1Y)
34.65%
Revenue / Employee
$477,374
Profits / Employee
-$69,731
Market Cap
31.99B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4,434 | 1,141 | 34.65% |
| Dec 31, 2023 | 3,293 | 275 | 9.11% |
| Dec 31, 2022 | 3,018 | 348 | 13.03% |
| Dec 31, 2021 | 2,670 | 855 | 47.11% |
| Dec 31, 2020 | 1,815 | 776 | 74.69% |
| Dec 31, 2019 | 1,039 | 64 | 6.56% |
| Dec 31, 2018 | 975 | 82 | 9.18% |
| Dec 31, 2017 | 893 | 41 | 4.81% |
| Dec 31, 2016 | 852 | 136 | 18.99% |
| Dec 31, 2015 | 716 | 42 | 6.23% |
| Dec 31, 2014 | 674 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NTRA News
- 2 days ago - Natera, Inc. (NTRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 3 days ago - Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling - Business Wire
- 4 days ago - Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA - Business Wire
- 4 days ago - Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth - Business Wire
- 9 days ago - Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer - Business Wire
- 11 days ago - Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI - Business Wire
- 11 days ago - Natera Launches 21-Gene Fetal Focus™ Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP™ Technology - Business Wire
- 25 days ago - Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Business Wire